Related Experiment Videos
Genetics of metachromatic leukodystrophy
V Gieselmann1, J Kreysing, K von Figura
1Georg-August-Universität, Göttingen.
Gene Therapy
|January 1, 1994
Summary
Metachromatic leukodystrophy (MLD) is a genetic disorder caused by arylsulfatase A (ASA) deficiency, leading to progressive demyelination. Research is advancing understanding and developing a mouse model for therapeutic strategies.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease.
- It results from arylsulfatase A (ASA) deficiency, causing cerebroside sulfate accumulation.
- This accumulation primarily affects myelinating oligodendrocytes, leading to progressive demyelination and neurological decline.
Purpose of the Study:
- To investigate the molecular basis of Metachromatic Leukodystrophy (MLD).
- To establish genotype-phenotype correlations in MLD patients.
- To develop a mouse model for studying MLD pathogenesis and therapeutic interventions.
Main Methods:
- Cloning of arylsulfatase A (ASA) cDNA and gene.
- Identification and analysis of disease-causing mutations.
- Development of a mouse model using homologous recombination in embryonic stem cells.
Main Results:
- The cDNA and gene for ASA have been successfully cloned.
- Numerous disease-causing mutations have been identified.
- A straightforward correlation between genotype and phenotype has been established.
Conclusions:
- Understanding MLD's genetic basis is crucial for diagnosis and potential treatments.
- The identified mutations and genotype-phenotype correlations aid in disease characterization.
- The developed mouse model is essential for future research into MLD pathogenesis and therapy.